What Kincell Bio does

Kincell Bio is a U.S.-based cell therapy contract development and manufacturing organization (CDMO) founded in 2023 as a spinout of Inceptor Bio, headquartered in Gainesville, FL with a second facility in Research Triangle Park, NC. The company provides end-to-end CMC services to biotechnology and pharmaceutical companies developing engineered immune cell therapies, including process development, analytical development, GMP manufacturing, characterization and release testing, and tech transfer. Its modalities span CAR-T, CAR-NK, CAR-M, TCR-T, differentiated iPSC, and Treg programs across both autologous (one-batch, one-patient) and allogeneic (scalable, off-the-shelf) manufacturing models.

The platform is anchored in a two-site GMP manufacturing network with standardized process platforms enabling tech transfer from early-phase clinical supply in Gainesville to pivotal and commercial manufacturing in RTP. Kincell Bio sells directly to cell therapy sponsors through enterprise field sales, supported by content marketing, conference presence (CAR-TCR, Meeting on the Mesa, BIO, ASGCT, ISCT, CPHI), webinars, and LinkedIn thought leadership. Pricing is quote-based and negotiated per program; revenue is project-based with long-term, milestone-aligned contracts. The company has raised approximately $58 million in disclosed funding and is currently expanding the RTP facility to add two ISO 7 cleanrooms, additional QC, microbiology, and MSAT labs, expanded warehouse, and capacity for 100+ team members, with full operations targeted for Q3 2026. Leadership includes veterans from Catalent, Thermo Fisher, Brammer Bio, Resilience, Lyell, Fred Hutch, Pfizer, and Novartis, with Executive Chair Mark Bamforth having previously founded and exited three CDMOs.

Name

Kincell Bio

Legal name

Kincell Bio

Website

https://kincellbio.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

51–100 employees

Short description

Kincell Bio is a U.S.-based cell therapy CDMO providing CMC development, process development, analytical services, and GMP manufacturing for autologous and allogeneic immune cell therapies (CAR-T, CAR-NK, TCR-T, iPSC, Treg) from facilities in Gainesville, FL and Research Triangle Park, NC.

Ownership category

akta.pro rank

Product category

Cell Therapy CDMO Services

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Cell Therapy CDMO (HLAGABAD)

akta.pro secondary industry

Cell Therapy CDMO (Autologous/Allogeneic Manufacturing) (HLAGAGAA)

Keywords

• Cell therapy CDMO
• Contract manufacturing services
• CMC development
• GMP manufacturing
• Process development

Headquarters

HQ city

Gainesville

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Contract Development and Manufacturing Services: Kincell Bio generates revenue through contract manufacturing and development services for cell therapy companies. Services include CMC roadmap development, process development, analytical development, GMP manufacturing, characterization and release testing, and tech transfer services. Revenue is project-based with long-term contracts typically aligned with client program milestones from early clinical through commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Kincell Bio is a cell therapy Contract Development and Manufacturing Organization (CDMO) that provides integrated services across the full cell therapy product lifecycle for autologous and allogeneic programs including CAR-T, CAR-NK, CAR-M, TCR-T, iPSC, and Treg therapies. Services span CMC roadmap development, process and analytical development, GMP manufacturing, characterization and release testing, and tech transfer, delivered across two U.S. facilities in Gainesville, FL and Research Triangle Park, NC.

Product overview

Kincell Bio is a leading cell therapy CDMO (Contract Development and Manufacturing Organization) offering integrated services across the full cell therapy product lifecycle. The company's portfolio includes six core services: CMC Roadmap & Development, Early & Late Phase Process Development, Analytical Development & Methods, Clinical & Commercial GMP Manufacturing, Characterization & Release Testing, and Transfer In Playbook. These services support three development phases (Early-Phase Acceleration, Late-Phase Development, and Commercialization & Commercial Supply) and two therapy modalities (Autologous and Allogeneic Cell Therapies). Quality and regulatory support is provided through Quality Culture & Regulatory Support and PAI Readiness Program. The company operates two U.S. facilities (Gainesville, FL and Research Triangle Park, NC) providing end-to-end capabilities from concept through commercial supply.

Differentiator

Problem solved

Functional benefit

Products and services

• CMC Roadmap & Development Strategic CMC roadmaps built for speed, rigor, and commercial success, helping innovators move cell therapies from concept to IND through structured CMC strategy, DoE-driven process development, and phase-appropriate analytics. Intended for cell therapy developers needing early-phase CMC planning.
• Early & Late Phase Process Development Risk-based process development services from early feasibility through commercialization, integrating process optimization, control strategy strengthening, and scalable GMP execution. For cell therapy developers progressing from early feasibility to late-phase manufacturing.
• Analytical Development & Methods Phase-appropriate platform methods, custom-developed and validated methods, in-process testing, tracking, and trending to ensure safety, potency, and consistency. For cell therapy developers needing identity, potency, and safety analytical data.
• Clinical & Commercial GMP Manufacturing Reliable, PAI-ready GMP manufacturing from early clinical through commercial supply, ensuring consistent, patient-ready cell therapy production across two U.S. facilities (Gainesville, FL and Research Triangle Park, NC). For cell therapy sponsors needing clinical and commercial GMP supply.
• Characterization & Release Testing Expert release testing and characterization ensuring safety and potency, building a foundation for quality and regulatory success through CQA-driven approaches and platform methods. For cell therapy developers requiring lot release and characterization support.
• Transfer In Playbook Structured 8-point tech transfer playbook ensuring smooth program transitions using risk-based planning, cross-functional expertise, and phase-appropriate quality controls. For sponsors transferring cell therapy programs into Kincell's facilities.
• Early-Phase Acceleration Risk-managed CMC roadmaps, DoE-driven process optimization, and phase-appropriate analytics balancing rapid IND readiness with long-term commercial strategy. For cell therapy sponsors preparing for IND filing and first-in-human studies.
• Late-Phase Development Strengthened control strategies, process characterization, and comparability planning aligning analytical rigor, manufacturing scalability, and regulatory readiness for pivotal studies and BLA preparation. For sponsors advancing toward pivotal trials.
• Commercialization & Commercial Supply Inspection-ready GMP operations, scalable manufacturing platforms, validated analytical control strategies, and supply chain resilience ensuring reliable, cost-conscious commercial supply. For sponsors of approved and late-stage cell therapies.
• Autologous Cell Therapy CDMO Disciplined scale-out manufacturing for autologous therapies with one-batch, one-patient model, strict chain-of-identity controls, and scalable GMP production. For sponsors of patient-derived cell therapies such as CAR-T.
• Allogeneic Cell Therapy CDMO Scalable allogeneic cell therapy manufacturing enabling off-the-shelf treatments with robust cell banking, scalable expansion platforms, and commercial-ready automation. For sponsors of donor-derived or renewable cell source therapies.
• Quality Culture & Regulatory Support Embedding quality and regulatory readiness into every phase of cell therapy development with integrated CMC, analytics, and quality systems for inspection-ready operations. For sponsors needing integrated quality and regulatory support across development and manufacturing.
• PAI Readiness Program PAI readiness built into everyday operations through regulatory mapping, phase-appropriate requirements, extensive operator training, data integrity, and analytical method readiness. For sponsors preparing for FDA pre-approval inspection.

Quantifiable outcome

• Supporting clients advancing from late-stage clinical CMC development through commercialization and post-approval lifecycle management for both autologous and allogeneic cell therapy programs
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• RegCellcoreStrategic or Co-development Partner · 10 February 2026Kincell Bio announced a partnership with RegCell, a biotechnology company developing Treg cell therapies for autoimmune diseases. Under the partnership, Kincell provides CMC development and GMP manufacturing support to accelerate RegCell's lead Treg program toward clinical trials, including process transfer, scalable manufacturing development, and clinical material supply for IND-enabling activities. RegCell's platform is based on epigenetically reprogrammed regulatory T cells developed by co-founder Professor Shimon Sakaguchi, the 2025 Nobel Prize laureate in Physiology or Medicine.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Resilience: U.S.-based cell and gene therapy CDMO offering process development, GMP manufacturing, and analytical services across modalities including autologous and allogeneic therapies. Direct competitor for the same biotech customer base, with overlapping service lines and similar facility footprint scale.
• WuXi Advanced Therapies Unit: Cell and gene therapy manufacturing services arm of WuXi AppTec/WuXi Biologics, offering process development, viral vectors, and cell therapy manufacturing. Direct competitor with substantial scale, though geopolitical and biosecurity policy risks have complicated its U.S. market position, opening room for Kincell.

Broad incumbents

• Catalent (Novo Holdings): One of the largest global CDMOs with a dedicated cell and gene therapy business acquired by Novo Holdings in 2024. Offers a broad portfolio that includes cell therapy manufacturing, viral vectors, and biologics; competes with Kincell for cell therapy contracts but as part of a much larger service portfolio.
• Lonza Cell & Gene Technologies: Global CDMO leader with extensive cell and gene therapy manufacturing capacity, including autologous and allogeneic platforms. Competes with Kincell for commercial-scale cell therapy supply contracts and represents one of the most likely strategic acquirers or partners for emerging cell therapy CDMOs.
• Charles River Laboratories: Large CRO/CDMO offering cell therapy manufacturing, viral vector production, and integrated discovery-to-commercial services. Competes with Kincell primarily through its Cell & Gene Therapy CDMO segment and brings significantly broader scientific services and global reach.
• AGC Biologics: Global CDMO providing cell therapy, viral vector, and biologics manufacturing services with facilities in the U.S. and Europe. Competes with Kincell for cell therapy developers seeking integrated CMC and GMP services at commercial scale.

Emerging players

• Cellares: Cell therapy manufacturing technology company developing automated, closed-system Cell Shuttle platforms for autologous cell therapy production. Represents both a potential partner for Kincell's autologous work and a competitive threat if sponsors adopt in-house automated manufacturing.
• Genezen: U.S.-based cell and gene therapy CDMO offering viral vector, cell therapy, and analytical services from its Indianapolis facility. Comparable size and growth stage to Kincell, serving a similar early-to-mid-stage biotech customer base.
• Wheeler Bio: Emerging U.S. CDMO offering Portable CMC antibody and cell therapy process development and GMP services. Comparable scale and customer segment to Kincell; Kincell's Chief Commercial Officer previously launched Wheeler's Portable CMC service.
• Matica Biotechnology: Cell and gene therapy CDMO offering viral vector and cell therapy manufacturing from a Texas facility. Comparable scale to Kincell with overlapping customer segments in early-to-mid-stage cell and gene therapy developers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/kincellbio

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kincell Bio